Results 71 to 80 of about 13,549 (163)
Cancer Medicine, 2023 Background Carfilzomib is a selective proteasome inhibitor approved for treating relapsed or refractory multiple myeloma (RRMM). Carfilzomib improves overall survival (OS) and progression‐free survival (PFS); however, treatment with carfilzomib results ...
Hiromi Hagiwara +7 more
doaj +1 more source
Neutrophils: Heterogeneity, Biology, Diseases, and Therapeutic Strategies
MedComm, Volume 7, Issue 11, November 2026.Neutrophils exhibit remarkable functional plasticity and play dual roles in tissue protection and disease progression. This review summarizes their key biological functions and highlights the shift from conventional broad‐spectrum interventions to neutrophil‐based drug delivery systems.
Yibing Zhang +4 more
wiley +1 more source
Covalent drug discovery: Progress against key targets, emerging strategies and lessons learnt
British Journal of Pharmacology, Volume 183, Issue 22, Page 6574-6606, November 2026.Abstract Covalent drug discovery is currently experiencing a boom in industrial and academic interest. To date, at least 75 covalent drugs have received regulatory approval, targeting both traditional target classes and more challenging proteins for which other approaches failed. In many cases, unique aspects of covalent targeting are essential for the
Charles P. Brown +2 more
wiley +1 more source
European Journal of Haematology, Volume 117, Issue 5, Page 1181-1197, November 2026.ABSTRACT Multiple myeloma (MM) is predominantly a disease of older adults, yet the randomized clinical trials (RCTs) that define standards of care are conducted largely in younger, fitter, and less comorbid populations. This creates a systematic mismatch between the populations generating evidence and those receiving treatment in routine practice ...
Enrica Antonia Martino +13 more
wiley +1 more source
Drug Design, Development and Therapy, 2018 Fang Zhao,1 Bo Yang,2 Juan Wang,1 Rui Zhang,1 Jing Liu,1 Fenglei Yin,1 Weixing Xu,1 Chunyuan He1 1Department of Hematology, Cangzhou Central Hospital, Cangzhou, People’s Republic of China; 2Department of Thoracic Surgery, Cangzhou Central Hospital,
Zhao F +7 more
doaj
Advanced Science, Volume 13, Issue 57, 14 October 2026.This study reports D34 as the first PROTAC degrader that targets the 3C protease of picornaviruses. D34 effectively degrades EV71 3C protease via the ubiquitin‐proteasome pathway. More importantly, D34 exhibits a high resistance barrier and shows broad‐spectrum antiviral activity against multiple picornaviruses, highlighting its potential as a novel ...
Weilong Deng +9 more
wiley +1 more source
POEMS Syndrome: 2026 Update on Diagnosis, Risk‐Stratification, and Management
American Journal of Hematology, Volume 101, Issue 10, Page 2632-2651, October 2026.ABSTRACT Disease Overview POEMS syndrome is a life‐threatening syndrome due to an underlying plasma cell neoplasm. The major criteria for the syndrome are polyneuropathy, clonal plasma cell disorder (PCD), sclerotic bone lesions, elevated vascular endothelial growth factor, and the presence of Castleman disease.
Angela Dispenzieri
wiley +1 more source
Targeted treatments for multiple myeloma: specific role of carfilzomib
, 2015 Dhivya Sugumar,1 Jesse Keller,2 Ravi Vij2 1Department of Internal Medicine, St Mary’s Health Center, 2Department of Medicine, Division of Oncology, Washington University in St Louis, St Louis, USA Abstract: Carfilzomib is a selective, irreversible
Sugumar D, Vij R, Keller J
core
American Journal of Hematology, Volume 101, Issue 10, Page 2546-2556, October 2026.ABSTRACT Cardiovascular adverse events (CVAEs) associated with bispecific T‐cell engaging antibodies (BsAbs) have not been systematically investigated across approved agents. In this disproportionality analysis of FAERS (December 2014–September 2025), reports listing BsAbs as the primary suspected drug (n = 7647) were compared with all other drugs in ...
Malak Munir +9 more
wiley +1 more source